ClinicalTrials.gg
CompletedNCT03957694Updated May 26, 2022

Study of AMG531(Romiplostim) in Patients With Aplastic Anemia

A Phase 2/3 interventional study of Romiplostim in Aplastic Anemia, sponsored by Kyowa Kirin Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-05-26.

Sponsored by Kyowa Kirin Co., Ltd. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing romiplostim in Anemia, Aplastic — 6 open to participants now, 6 under way, 1 of them phase 3. romiplostim · Anemia, Aplastic.

Enrollment
10th of 15
17 · median 35
Started
2019
with 1 other
Phase 2/3
3 of 15
none open now
Registered
3rd of 15
by date
Lead sponsor
3 of 15
Kyowa Kirin Co., Ltd.

Among the 15 studies testing romiplostim in Anemia, Aplastic, this one is the 10th largest by enrollment, is one of 2 that started in 2019, is one of 3 in phase 2/3, and was the 3rd registered.

Anemia, Aplastic

372 studies on the registry are indexed under Anemia, Aplastic; 99 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

6 of the 15 studies testing romiplostim in Anemia, Aplastic are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About romiplostim

romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 59 Anemia, Aplastic studies recruiting now, 21 (36%) set no upper age limit and 30 (51%) stop at 75 or younger; 38 take children under 18; 5 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing romiplostim in Anemia, Aplastic, or all of them as a file.
02

Study summary

To evaluate the hematological responses based on the response assessment criteria when AMG531 is subcutaneous (SC)-administered with anti-human thymocyte immunoglobulin (ATG) + ciclosporin A (CsA) therapy for 6 months in patients with aplastic anemia (AA) who were previously untreated with immunosuppressive therapy.

03

Conditions studied

  • Aplastic Anemia

Browse trials for

Keywords

  • aplastic anemia
  • romiplostim
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary signed to participate in the study;
  2. A diagnosis of AA confirmed by blood and bone-marrow examinations, etc.;
  3. Considered to require new treatment with ATG and CsA provided that NSAA must be or erythrocyte transfusion-dependent.
  4. An (ECOG) performance status (PS) score of 0 to 1at screening

Exclusion criteria

Exclusion Criteria:

  1. Previously treated with ATG, CsA, or Alemtuzumab;
  2. Diagnosed as having congenital AA (Fanconi anemia, congenital dyskeratosis, etc.);
  3. Diagnosed as having AML or chronic myelomonocytic leukemia;
  4. Concurrent thrombocytopenia of other etiologies (e.g., MDS, ITP, cirrhosis);
  5. Concurrent active infection not adequately responding to appropriate therapy;
  6. Concurrent illness(es) items which are deemed by the Investigator to be likely to affect the study conduct and assessments.
  7. Having active , or having a history of treatment of malignancies within 5 years prior to .
  8. Concurrent PNH
  9. Having Grade 2 or higher bone marrow reticulin based on Bone Marrow Pathology (2nd edition) ;
  10. History of chromosome aberrations discovered in bone marrow cells.
  11. Having blast cells > 2% in bone marrow;
  12. Positive for anti- (HIV) antibody;
  13. Receiving prophylactic or therapeutic treatment for hepatitis type B
  14. Positive for virus (HCV) antibody, and HCV infection being confirmed
  15. Planned hematopoietic stem cell transplantation during the study;
  16. Systemic treatment with any of the following medication for the treatment of AA within 4 weeks before Day 1, however, excluding their use as premedication:

    • Anabolic steroids
    • ;
  17. Pregnant or breastfeeding women, or women willing to become pregnant;
  18. Other conditions unsuitable for participation in the study in the opinion of the Investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    AMG531

    Drug: Romiplostim

Interventions

  • Romiplostim SC. Initial dose is 10 ug/kg/. Maximum dose is 20 ug/kg. Original duration is 6 months from first administration but if investigator decide that the patient is needed more treatment, they move to extention period and take treatment up to 1 year.

06

What researchers measure

Primary outcomes

  1. Achievement of complete response (CR) or partial response (PR)

    Time frame: 27 weeks post-dose

Secondary outcomes

  1. Achievement of CR or PR

    Time frame: Week 14

  2. Achievement of CR

    Time frame: Weeks 14 and 27

  3. The time to CR or PR

    Time frame: Each time point evaluated weekly until Week 27

  4. Reduction or independence of platelet and/or erythrocyte transfusion

    Time frame: Week 27

  5. Change from baseline in platelet count (/µL)

    Time frame: Each time point evaluated weekly until Week 27

  6. Change from baseline in hemoglobin (Hb) concentration (g/dL)

    Time frame: Each time point evaluated weekly until Week 27

  7. Change from baseline in neutrophil count (/µL)

    Time frame: Each time point evaluated weekly until Week 27

  8. Change from baseline in reticulocyte count (/µL)

    Time frame: Each time point evaluated weekly until Week 27

07

Study locations

1 site
  • Matsuyama Red Cross Hospital
    Ehime, Japan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Nov 2020, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2019
First posted
May 21, 2019
StartActual
Apr 25, 2019
Primary completionActual
Nov 5, 2020
CompletionActual
May 26, 2021
Last update
May 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03957694
Responsible party
Sponsor
First posted
May 21, 2019
Start date
Apr 25, 2019
Primary completion
Nov 5, 2020
Completion
May 26, 2021
Last update
May 26, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion